This is only partially correct..the only suture share/profit Ethicon has lost has been to knotless suture, due to a terrible contract that was negotiated with angiotech allowing quill to drop their price as soon as the ink was dry. Ethicon has taken a ridiculous amount of time getting even close to a full portfolio of knotless options, specifically for lap or robotic use, further allowing vloc to take share.
None of this had anything to do with the rep model or knowledge. This has solely been the fault of the organization.
Ethicon has not lost market share on regular suture.
